Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL

被引：0
|
作者：
Zhu, Fenlu [1 ]
Shah, Nirav N. [2 ]
Schneider, Dina [3 ]
Xu, Huiqing [1 ]
Chaney, Katherine [4 ]
Luib, Lawrence [5 ]
Keever-Taylor, Carolyn [6 ]
Dropulic, Boro [3 ]
Orentas, Rimas [7 ]
Hari, Parameswaran [2 ]
Johnson, Bryon D. [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, BMT & Cellular Therapy Program, Hematol Oncol, Med, Milwaukee, WI 53226 USA
[3] Lentigen Technol Inc, Gaithersburg, MD USA
[4] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
[5] Froedtert Hosp, Milwaukee, WI USA
[6] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[7] Seattle Childrens Hosp, Seattle, WA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [32] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
    Liu, Hui
    Lei, Wen
    Zhang, Chaoting
    Yang, Chunmei
    Wei, Juying
    Guo, Qunyi
    Guo, Xiaojun
    Chen, Zhilu
    Lu, Ying
    Lu, Zheming
    Qian, Wenbin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] MANAGING RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS ON A PHASE I TRIAL RECEIVING AUTOLOGOUS CAR (CHIMERIC ANTIGEN RECEPTOR) T-CELLS GENETICALLY MODIFIED TO TARGET B CELL SPECIFIC ANTIGEN CD19
    Quintanilla, Hilda S.
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E102 - E103
  • [35] Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
    Wang, Chun-Meng
    Wu, Zhi-Qiang
    Wang, Yao
    Guo, Ye-Lei
    Dai, Han-Ren
    Wang, Xiao-Hui
    Li, Xiang
    Zhang, Ya-Jing
    Zhang, Wen-Ying
    Chen, Mei-Xia
    Zhang, Yan
    Feng, Kai-Chao
    Liu, Yang
    Li, Su-Xia
    Yang, Qing-Ming
    Han, Wei-Dong
    CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1156 - 1166
  • [36] Phase I/II Trial of Multi Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 13 - 14
  • [37] A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+Lymphomas
    Grover, Natalie S.
    Park, Steven I.
    Ivanova, Anastasia
    Eldridge, Paul
    McKay, Kathryn
    Cheng, Catherine
    Laing, Spencer
    Covington, Deborah
    West, John
    Sharf, Elizabeth
    Morrison, J. Kaitlin
    Scott, Shaw
    Crecelius, Erin
    Shelley, Desirae
    Alexander, Maurice
    Buchanan, Faith Brianne
    Kassam, Emily
    McElfresh, Megan
    Pinto, Alicia
    Spruill, Angela
    Zanter, Ashley
    Wehner, Kimberly
    Dittus, Christopher
    Shea, Thomas C.
    Dotti, Gianpietro
    Serody, Jonathan S.
    Beaven, Anne
    Savoldo, Barbara
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [38] A Phase I/II Clinical Trial of Piggybac-Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies
    Saito, Shoji
    Tanaka, Miyuki
    Hasegawa, Aiko
    Inada, Yoichi
    Morokawa, Hirokazu
    Usami, Yoko
    Kojima, Shunsuke
    Yanagisawa, Ryu
    Miyazawa, Chinatsu
    Ito, Keiko
    Sakai, Hitoshi
    Nakazawa, Hideyuki
    Tashiro, Haruko
    Yagyu, Shigeki
    Nakazawa, Yozo
    BLOOD, 2021, 138
  • [39] A Phase I/II Clinical Trial of Piggybac-Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies
    Saito, Shoji
    Tanaka, Miyuki
    Morokawa, Hirokazu
    Hirabayashi, Koichi
    Inada, Yoichi
    Usami, Yoko
    Kojima, Shunsuke
    Yanagisawa, Ryu
    Nakazawa, Hideyuki
    Nakazawa, Yozo
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [40] Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia
    Ghafouri, Sanaz
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Mead, Monica
    Timmerman, John M.
    Chen, Yvonne
    Larson, Sarah
    BLOOD, 2020, 136
12345